Skip to main content

Table 3 Treatment duration in each treatment arm by simplified MIPI risk category [13,14]

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Treatment Low risk Intermediate risk High risk
Temsirolimus 175/75 mg    
 n 14 24 16
 Mean (std dev), weeks 32.4 (22.0) 21.1 (24.8) 10.5 (8.8)
Temsirolimus 175/25 mg    
 n 15 18 21
 Mean (std dev), weeks 39.0 (42.3) 17.6 (11.4) 11.7 (12.4)
INV therapy    
 n 21 21 11
 Mean (std dev), weeks 8.1 (7.8) 9.8 (10.3) 3.3 (2.4)
  1. MIPI = Mantle Cell Lymphoma International Prognostic Index; std dev = standard deviation; INV = Investigator’s choice.